![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High SVR24 rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV genotype (G)1/4-infected treatment-naive patients: the DAUPHINE study
|
|
|
Reported by Jules Levin
APASL - Asian Pacific Association for the Study of the Liver (APASL) Liver Week, June 6-10, 2013, Singapore
![Conclusion.gif](../images/060913/060913-5/Conclusion.gif)
![APASL2.gif](../images/060913/060913-5/APASL2.gif)
![APASL3.gif](../images/060913/060913-5/APASL3.gif)
![APASL4.gif](../images/060913/060913-5/APASL4.gif)
![APASL5.gif](../images/060913/060913-5/APASL5.gif)
![APASL6.gif](../images/060913/060913-5/APASL6.gif)
![APASL7.gif](../images/060913/060913-5/APASL7.gif)
![APASL8.gif](../images/060913/060913-5/APASL8.gif)
![APASL9.gif](../images/060913/060913-5/APASL9.gif)
![APASL10.gif](../images/060913/060913-5/APASL10.gif)
![APASL11.gif](../images/060913/060913-5/APASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|